Research SummaryKey Findings

What research findings exist for Mazdutide in weight loss and weight management?

Significant weight loss in all dose groups at 32 weeks compared with placebo. Another study reported: at 60 weeks, the 9mg group had an average weight change of about -16.65%, placebo about -1.50%.[1] ↗ [2] ↗

Before ReadingStudy populations, species, formulations and delivery conditions each have a defined scope. Research on an ingredient does not establish that this site's product batches have been validated for efficacy in humans or veterinary use.
i

Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.

Comparison of study design and results

Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.

LiteratureStudy subjects and designObservation and discoveryScope of Explanation
2026 · PMID 42628555United States, 179 adults, randomized Phase II trialSignificant weight loss in all dose groups at 32 weeks compared with placebo.Dose exploration and specific trial formulations.
2026 · PMID 42251595461 obese adults in China; GLORY-2 randomized trial.At week 60, the 9mg group had an average weight change of about -16.65%, placebo about -1.50%.Population and follow-up restrictions; Does not represent the website's 5mg bottle usage.
2026 · PMID 41875890China, 80 adults with BMI ≥30 and no diabetes, randomized Phase II24-week 9mg group weight loss about 12.78%, better than placebo.Small-sample trial, cannot generalize to all weight populations.

References

Human Study2026REF. 01

What were the findings of Mazdutide dose exploration in the U.S. population?

Research Findings

Significant weight loss in all dose groups at 32 weeks compared with placebo.[1] ↗

Study Design

United States, 179 adults, randomized Phase II trial

Scope & Limitations

Dose exploration and specific trial formulations.

View the Article Title and Full Citation＋

Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.

Hsia SH, Bays HE, Billings LK, Weideman AMK, Mather KJ, Coskun T, Haupt A, Thomas MK, Tham LS, Calderon B, Ni W, De Araujo OFG.

The Lancet. Diabetes & Endocrinology · Volume and issue year 2026
First published 2026-08-21 · PMID 42628555
DOI 10.1016/s2213-8587(26)00160-9

Published · Original ResearchPubMed ↗Journal Article ↗
Human Study2026REF. 02

What did the long-term weight study of GLORY-2 observe?

Research Findings

At week 60, the 9mg group had an average weight change of about -16.65%, placebo about -1.50%.[2] ↗

Study Design

461 obese adults in China; GLORY-2 randomized trial.

Scope & Limitations

Population and follow-up restrictions; Does not represent the website's 5mg bottle usage.

View the Article Title and Full Citation＋

Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.

Gao L, Jiang H, Cai H, Tian J, Shi B, Qiu W, Huang C, Han J, Zhang S, Pang S, Bi Y, Chen L, Gu X, Han J, Ma Q, Deng H, Wang Y, Li L, Han-Zhang H, Qian L, Ji L, GLORY-2 Trial Investigators.

JAMA · Volume/Issue/Year 2026
First published 2026-08-01 · PMID 42251595
DOI 10.1001/jama.2026.8142

Published · Original ResearchPubMed ↗Journal Article ↗
Human Study2026REF. 03

What were the findings of the early dose trial in obese adults in China?

Research Findings

24-week 9mg group weight loss about 12.78%, better than placebo.[3] ↗

Study Design

China, 80 adults with BMI ≥30 and no diabetes, randomized Phase II

Scope & Limitations

Small-sample trial, cannot generalize to all weight populations.

View the Article Title and Full Citation＋

Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m<sup>2</sup> but without diabetes: A phase 2 randomized controlled trial.

Ji L, Jiang H, Cheng Z, Li X, Pang S, Zhang Y, Qiu W, Ma Q, Liu Z, Wang Y, Deng H, Du H, Han-Zhang H, Qian L.

Med (New York, N.Y.) · Volume/Issue Year 2026
First published 2026-03-23 · PMID 41875890
DOI 10.1016/j.medj.2026.101063

Published · Original ResearchPubMed ↗Journal Article ↗

Common issues and corresponding evidence

What research findings exist for Mazdutide in weight loss and weight management?＋

Significant weight loss in all dose groups at 32 weeks compared with placebo. Another study reported: at 60 weeks, the 9mg group had an average weight change of about -16.65%, placebo about -1.50%.[1] ↗ [2] ↗

Can the dosage used in Mazdutide weight loss trials be directly applied to bottled specifications?＋

Not possible. Escalation schemes, follow-ups, and trial formulations in human trials are complete conditions; the total amount in a single bottle does not equal a single dose, nor can it predict the degree of individual weight loss.[1] ↗ [2] ↗ [3] ↗

Mazdutide—these conclusions apply to which study populations?＋

United States, 179 adults, randomized Phase II trial; China, 461 obese adults; GLORY-2 randomized trial; China, 80 adults with BMI≥30 without diabetes, randomized Phase II trial. Dose exploration and specific trial formulations.[1] ↗ [2] ↗ [3] ↗

Mazdutide

Return to catalog specifications and batch file verification entry.

↗